Amylyx Pharmaceuticals, Inc.
AMLX
$32.91
-$0.97-2.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.34% | -100.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.34% | -100.08% |
| Cost of Revenue | 3.09% | -27.79% | -71.52% | -74.31% | -74.75% |
| Gross Profit | -2.72% | 28.72% | 53.91% | -6.09% | -372.12% |
| SG&A Expenses | 5.15% | -12.29% | -44.99% | -56.79% | -63.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.98% | -6.36% | -55.31% | -61.75% | -64.62% |
| Operating Income | -0.83% | 7.05% | 40.04% | 26.16% | -3.78% |
| Income Before Tax | 19.23% | 31.63% | 52.11% | 41.78% | -15.93% |
| Income Tax Expenses | 107.24% | 107.24% | 111.70% | -131.96% | -118.12% |
| Earnings from Continuing Operations | 18.93% | 31.41% | 52.03% | 42.47% | -13.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.93% | 31.41% | 52.03% | 42.47% | -13.10% |
| EBIT | -0.83% | 7.05% | 40.04% | 26.16% | -3.78% |
| EBITDA | -1.03% | 6.92% | 40.04% | 26.07% | -4.10% |
| EPS Basic | 42.67% | 51.43% | 64.99% | 52.85% | -2.45% |
| Normalized Basic EPS | 30.07% | 34.80% | 56.87% | 36.34% | 3.57% |
| EPS Diluted | 42.67% | 51.43% | 64.99% | 52.86% | -2.00% |
| Normalized Diluted EPS | 30.07% | 34.80% | 56.87% | 36.31% | 4.01% |
| Average Basic Shares Outstanding | 36.41% | 38.73% | 38.69% | 24.09% | 15.08% |
| Average Diluted Shares Outstanding | 36.41% | 38.73% | 38.69% | 23.28% | 13.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |